Stockscreener 앱 받기
280.96
1.15%
-3.27
전일 마감가:
$284.23
열려 있는:
$284.655
하루 거래량:
376.48K
Relative Volume:
0.47
시가총액:
$19.77B
수익:
$2.20B
순이익/손실:
$402.20M
주가수익비율:
50.53
EPS:
5.56
순현금흐름:
$280.80M
1주 성능:
-3.78%
1개월 성능:
-7.32%
6개월 성능:
+1.77%
1년 성능:
+44.06%
1일 변동 폭
$280.43
$288.00
1주일 범위
$280.43
$293.17
52주 변동 폭
$173.00
$329.33
인슐렛 코퍼레이션 Stock (PODD) Company Profile
명칭
Insulet Corporation
전화
978-600-7000
주소
100 NAGOG PARK, ACTON, MA
PODD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
280.96 | 20.55B | 2.20B | 402.20M | 280.80M | 5.56 |
|
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
인슐렛 코퍼레이션 Stock (PODD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-05-13 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-06 | 개시 | Bernstein | Outperform |
| 2024-05-30 | 개시 | Redburn Atlantic | Buy |
| 2024-05-07 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-21 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-08-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 개시 | Wolfe Research | Peer Perform |
| 2022-11-04 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-07-28 | 개시 | Wells Fargo | Overweight |
| 2020-04-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 개시 | BofA/Merrill | Neutral |
| 2020-03-31 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-10 | 개시 | CFRA | Sell |
| 2019-10-23 | 개시 | Stifel | Hold |
| 2019-10-18 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-10-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-10-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-06-10 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-04-20 | 개시 | Berenberg | Buy |
| 2018-02-22 | 재확인 | Barclays | Overweight |
| 2018-01-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 개시 | Barclays | Overweight |
모두보기
인슐렛 코퍼레이션 주식(PODD)의 최신 뉴스
What analysts say about Insulet Corporation stockHigh-profit trading signals - jammulinksnews.com
Is Insulet Corporation a good long term investmentHigh-yield market plays - Autocar Professional
Digital Diabetes Management Market is projected to reach US$ - openPR.com
Insulet Corporation Stock Analysis and ForecastTremendous return on equity - Autocar Professional
What drives Insulet Corporation stock priceOutstanding risk-reward balance - Autocar Professional
$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today - Benzinga
Navigating the Crossroads: Insulet's Short-Term Volatility and Long-Term Growth Potential - AInvest
Insulet's PODD Stock Plunges 2.72% Amid Market Uncertainty - AInvest
Smart Pumps Market is projected to reach USD 19.96 billion by 2033 - openPR.com
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Leading Insulin Pump Maker Insulet to Release Q2 2025 Results August 7Key Details for Investors - Stock Titan
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
Trading (PODD) With Integrated Risk Controls - news.stocktradersdaily.com
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks? - MSN
5 Insightful Analyst Questions From Insulet’s Q1 Earnings Call - Yahoo Finance
When Should You Buy Insulet Corporation (NASDAQ:PODD)? - Yahoo Finance
Pump manufacturers: Patches are the fix for low AID uptake - BioWorld MedTech
Insulet Stock Plummets 30.61% with $196M Trading Volume Ranking 493rd Amid Omnipod 5 Recall - AInvest
How Is Insulet's Stock Performance Compared To Other Medical Devices Stocks? - Barchart.com
Insulet’s Eric Benjamin shares update on automated insulin delivery system - MedTech Dive
5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions - Business Wire
Truist bullish on diabetes companies citing potential market growth - MSN
Insulet’s SWOT analysis: patch pump leader’s stock poised for growth By Investing.com - Investing.com South Africa
Insulet’s SWOT analysis: patch pump leader’s stock poised for growth - Investing.com
Analyst Predicts Strong Growth for Insulet (PODD) with Buy Ratin - GuruFocus
Insider Sell: Dan Manea Sells 1,300 Shares of Insulet Corp (PODD) - GuruFocus
Insulet, EyePoint & NanoDx receive $2M in tax incentives to create life sciences jobs - Worcester Business Journal
Insulet (PODD) Rated 'Buy' by Truist Securities; Price Target Set at $365 | PODD Stock News - GuruFocus
(PODD) Investment Report - news.stocktradersdaily.com
Truist initiates Insulet stock with buy rating on diabetes pump potential - Investing.com Nigeria
Truist Initiates Insulet at Buy With $365 Price Target - MarketScreener
Truist Securities Starts Insulet Corporation (PODD) at Buy - StreetInsider
Insulet’s SWOT analysis: pump maker’s stock rides wave of growth By Investing.com - Investing.com South Africa
Insulet’s SWOT analysis: pump maker’s stock rides wave of growth - Investing.com
Trade secret misappropriation: permanent injunction and monetary damages - Reuters
Here's Why You Should Retain PODD Stock in Your Portfolio Now - MSN
Insulet Corporation (PODD): Can Margin Gains and Global Expansion Justify Its Premium? - AInvest
Insulet Boosts Its Diabetes Device Via Comical Campaign -- And A Comic Book 06/12/2025 - MediaPost
인슐렛 코퍼레이션 (PODD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
0.17%
자본화:
|
볼륨(24시간):